<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-02-02">February 02, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Julia</forename><surname>Onken</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurosurgery</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><surname>Torka</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Molecular Biology</orgName>
								<orgName type="department" key="dep2">Max-Planck Institute of Biochemistry</orgName>
								<address>
									<settlement>Martinsried</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sören</forename><surname>Korsing</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurosurgery</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Josefine</forename><surname>Radke</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Neuropathology</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Irina</forename><surname>Krementeskaia</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurosurgery</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Melina</forename><surname>Nieminen</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurosurgery</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xi</forename><surname>Bai</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurosurgery</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Axel</forename><surname>Ullrich</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Molecular Biology</orgName>
								<orgName type="department" key="dep2">Max-Planck Institute of Biochemistry</orgName>
								<address>
									<settlement>Martinsried</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Heppner</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Neuropathology</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Peter</forename><surname>Vajkoczy</surname></persName>
							<email>peter.vajkoczy@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurosurgery</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-02-02">February 02, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">B8B3866657D226D9DFE66111E7B3AA62</idno>
					<note type="submission">Received: October 20, 2015 Accepted: January 19, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:30+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>glioblastoma multiforme (GBM)</term>
					<term>small molecule inhibitor BMS-777607</term>
					<term>receptor tyrosine kinase AXL (RTK-AXL)</term>
					<term>invasion</term>
					<term>xenograft model</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Purpose: Receptor tyrosine kinase AXL (RTK-AXL) is regarded as suitable target in glioma therapy.</s><s>Here we evaluate the anti-tumoral effect of small molecule inhibitor BMS-777607 targeting RTK-AXL in a preclinical glioma model and provide evidence that RTK-AXL is expressed and phosphorylated in primary and recurrent glioblastoma multiforme (GBM).</s></p><p><s>Experimental design: We studied the impact of BMS-777607 targeting RTK-AXL in GBM models in vitro and in vivo utilizing glioma cells SF126 and U118MG.</s><s>Impact on proliferation, apoptosis and angiogenesis was investigated by immunohistochemistry (IHC) and functional assays in vitro and in vivo.</s><s>Tumor growth was assessed with MRI.</s><s>Human GBM tissue was analyzed in terms of RTK-AXL phosphorylation by immunoprecipitation and immunohistochemistry.</s></p><p><s>Results: BMS-777607 displayed various anti-cancer effects dependent on increased apoptosis, decreased proliferation and migration in vitro and ex vivo in SF126 and U118 GBM cells.</s><s>In vivo we observed a 56% tumor volume reduction in SF126 xenografts and remission in U118MG xenografts of more than 91%.</s><s>The tube formation assay confirmed the anti-angiogenic effect of BMS-777607, which became also apparent in tumor xenografts.</s><s>IHC of human GBM tissue localized phosphorylated RTK-AXL in hypercellular tumor regions, the migratory front of tumor cells in pseudopalisades, and in vascular proliferates within the tumor.</s><s>We further proved RTK-AXL phosphorylation in primary and recurrent disease state.</s></p><p><s>Conclusion: Collectively, these data strongly suggest that targeting RTK-AXL with BMS-777607 could represent a novel and potent regimen for the treatment of primary and recurrent GBM.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Malignant gliomas are the most common and most aggressive brain tumors due to their highly invasive growth pattern, proliferative capacities and heterogeneity <ref type="bibr" target="#b0">[1]</ref>.</s><s>Despite, multimodal aggressive therapy with chemotherapy, radiation, and surgery, less than 10% of patients with the diagnosis glioblastoma multiforme (GBM) survive 5 years beyond diagnosis <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>For the development of new therapeutic strategies it is unavoidable to understand the mechanisms of gliomagenesis and malignancy criteria of GBMs.</s><s>Current investigations aim to uncover novel therapeutic approaches by exploring the oncogenic mechanisms and unique potential targets of GBMs <ref type="bibr" target="#b3">[4]</ref>.</s></p><p><s>The receptor tyrosine kinase AXL (RTK-AXL) displays a new promising target in glioma therapy <ref type="bibr" target="#b4">[5]</ref>.</s><s>RTK-AXL is characterized by an extracellular domain consisting of two immunoglobulin-like domains in juxtaposition of two fibronectin type III domains, typical for cell adhesion molecules of the immunoglobulin superfamily <ref type="bibr" target="#b5">[6]</ref>.</s><s>The growth arrest-specific gene 6 (Gas6) is the natural ligand of RTK-AXL.</s><s>RTK-AXL/Gas6 signaling is in charge of regulating survival, proliferation, and migration in different types of cells in vitro, including tumor-derived epithelial, mesenchymal, and hematopoietic cell lines <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref>.</s><s>RTK-AXL/Gas6 overexpression has been described in a multitude of human cancers, including GBM, colon, breast, prostate, thyroid, lung cancer, and malignant melanoma <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b8">9]</ref>.</s><s>It has been shown that overexpression of RTK-AXL and Gas6 in GBM tissue is associated with reduced time to progression and overall survival in these patients <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11]</ref>.</s><s>Its oncogenic effect is explained by Gas6-dependent signaling through RTK-AXL resulting in phosphorylation of AKT and ERK 1/2 <ref type="bibr" target="#b11">[12]</ref>.</s><s>Furthermore, anti-apoptotic Bcl-2 family members (e.g., Bcl-2) are unregulated while pro-apoptotic family members (e.g., BAD) are inactivated <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14]</ref>.</s></p><p><s>Its exceptional role in GBM was presented in previous studies showing that experimental inhibition of the RTK-AXL pathway with dominant negative-mutant glioma cells of AXL receptor (SF126 AXL-DN) suppresses glioma growth and prolongs survival in orthotopic tumor model in mice <ref type="bibr" target="#b14">[15]</ref>.</s><s>SF126 AXL-DN cells display an attenuated locomotor or migration activity with reduced formation of filopodia and loss of cell-to-cell interaction.</s><s>Tumor cell motility is impaired in SF126 AXL-DN cells, which indicates that these cells are unable to invade normal brain tissue.</s><s>Previous results point to the fact that specific targeting of RTK-AXL supposes a promising approach to intervene GBM progression <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b16">17]</ref>.</s></p><p><s>Therefore, we studied a targeted inhibition of RTK-AXL phosphorylation with selective small molecule inhibitor BMS-777607 in vitro, ex vivo, and in vivo.</s><s>We observed significant regression of intracranial tumors due to treatment with BMS-777607.</s><s>These effects were mediated through increased apoptosis, reduced proliferation, migration, and neoangiogenesis.</s><s>According to the experimental results, we are the first to prove, that RTK-AXL is phosphorylated in human GBM tissue and that it is expressed in proliferating cells, in the migratory front of tumor cells, and in vascular proliferates.</s><s>Additionally, we demonstrate that RTK-AXL is strongly phosphorylated in both primary and recurrent GBMs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMS-777607 selectively blocks AXL phosphorylation in U118MG and SF126 cells in vitro and in vivo</head><p><s>The expression of RTK-AXL in U118MG and SF126 cells in vitro and in vivo was confirmed by immunofluorescence staining of adherent cells (Figure <ref type="figure" target="#fig_0">1A</ref>) and intracranial tumor tissue (Figure <ref type="figure" target="#fig_0">1B</ref>).</s><s>Western blot revealed a higher base line expression of RTK-AXL in U118MG compared to SF126 (Figure <ref type="figure" target="#fig_0">1C</ref>, left image).</s><s>We examined the phosphorylation of RTK-AXL under serum starved and standard conditions.</s><s>We detected an increase of P-AXL in cells cultured under starving conditions (DMEM without FCS) compared to individual cell line cultured with DMEM containing 10% FCS (Figure <ref type="figure" target="#fig_0">1C</ref>, right image).</s></p><p><s>The IC 50 value of BMS-777607 was determined for U118MG and SF126 at 4 and 12 hours after single treatment (Figure <ref type="figure" target="#fig_0">1D</ref>).</s><s>Specific inhibition of phosphorylation of RTK-AXL by BMS-777607 was confirmed in western blot analysis.</s><s>Following 12 hours of incubation, P-AXL was significantly reduced in both cell lines.</s><s>At the same time phosphorylation of RTK-MET was unaffected confirming the selectivity of BMS-777607 against RTK-AXL at a dosage of 12.5 µM (Figure <ref type="figure" target="#fig_1">2A</ref>).</s><s>We therefore addressed further results as RTK-AXL dependent.</s><s>Cell staining with anti-phospho-AXL antibody revealed membrane bound staining in both cell lines, which was reduced following incubation with the small molecule inhibitor of RTK-AXL BMS-777607 (Figure <ref type="figure" target="#fig_1">2B, 2C</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMS-777607 decreases glioma cell viability and induces glioma cell apoptosis in vitro</head><p><s>The exposure of U118MG and SF126 glioma cells with 12.5 µM BMS-777607 resulted in significantly reduced cell numbers in MTT assay after 24 hours of treatment (Figure <ref type="figure" target="#fig_1">2D</ref>, left image).</s><s>Single application of 12.5 µM BMS-777607 led to a significant increase of CPP32 activity in U118MG and SF126 cell lines after 24 hours (Figure <ref type="figure" target="#fig_1">2D</ref>, middle image).</s><s>We concluded that reduced cell viability by BMS-777607 resulted from the induction of apoptosis and reduction of proliferation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMS-777607 blocks glioma cell migration and invasive growth pattern</head><p><s>Next, we addressed the effects of BMS-777607 on glioma cell migration and invasion.</s><s>Blockage of RTK-AXL signaling with initial dose of 12.5 µM BMS-777607 resulted in a significant decrease of migration rate in U118MG and SF126 cells measured by Boyden Chamber Migration assay after 3 hours (Figure <ref type="figure" target="#fig_1">2D</ref>, left image).</s><s>Invasive growth pattern of glioma cells was studied in the orthotropic brain slice culture model, a three-dimensional invasion assay closely related to an in vivo situation as the structure and organization of the brain tissue are preserved <ref type="bibr" target="#b18">[19]</ref>.</s><s>Under control conditions, only U118MG cells, but not SF126 cells, demonstrated invasive growth in this assay.</s><s>Inhibition of RTK-AXL signaling with daily administration of 12.5 µM BMS-777607 abrogated tumor cell invasion into the brain tissue (Figure <ref type="figure" target="#fig_2">3A</ref>, right image).</s><s>Quantitative analysis using confocal microscopy confirmed this significant anti-invasive effect of BMS-777607 in this ex vivo model on day 8 (Figure <ref type="figure" target="#fig_2">3A</ref>, left image).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RTK-AXL is phosphorylated in HUVECs and inhibition displays antiangiogenic effect</head><p><s>RTK-AXL signaling has been also shown to be involved in endothelial cell proliferation and angiogenesis <ref type="bibr" target="#b4">(5)</ref>.</s><s>Thus, we additionally studied the effects of BMS-777607 on endothelial cell biology using in vitro assays with HUVECs.</s><s>Figure <ref type="figure" target="#fig_2">3B</ref> shows RTK-AXL expression and RTK-AXL phosphorylation in HUVECs.</s><s>The IC 50 value of BMS-777607 was assessed as shown in Figure <ref type="figure" target="#fig_2">3C</ref>.</s><s>In accordance to this result, tube formation assay was carried out with 12.5 µM BMS-777607.</s></p><p><s>Consistent with in vivo findings we proved direct effect of BMS-777607 on endothelial cells HUVEC in tube formation assay.</s><s>We observed a significant decrease of tube formation and branching points after 4 hours,</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>I.p. administration of BMS-777607 selectively blocks RTK-AXL signaling in vivo and inhibits intracranial tumor growth in mouse xenografts</head><p><s>For in vivo experiments, U118MG and SF126 cells were implanted stereotactically into the brains of CD1NuNu mice.</s><s>While U118MG xenografts showed a more invasive growth pattern, SF126 xenografts developed vascular proliferates, central necrosis and had a stronger proliferation rate (Supplementary Figure <ref type="figure" target="#fig_1">S2</ref>).</s></p><p><s>In both tumor models, treatment was initiated after proven tumor manifestation using MRI.</s><s>In the more aggressive tumor SF126 model, treatment was started at day 3 after implantation while treatment in the U118MG model was started on day 7 after implantation (Supplementary Figure <ref type="figure" target="#fig_2">S3</ref>).</s><s>In both models, BMS-777607 treatment (i.p. 2x/ day) resulted in a significant decrease of intracranial tumor growth on day 14 after implantation.</s><s>The most significant antitumor effect was seen in U118MG tumor model (Figure <ref type="figure" target="#fig_3">4A</ref>).</s><s>Here, 30 mg/kg BW BMS-777607 resulted in more than 90% tumor reduction after 6 days of treatment, in two cases we even observed complete tumor regression (n = 5, Figure <ref type="figure" target="#fig_3">4C</ref>, left image).</s><s>In the SF126 tumor model we detected a 56% tumor volume reduction.</s><s>Increase of dosage up to 100 mg/ kg BW lead to further regression.</s><s>We showed that BMS-777607 displayed a dose dependent effect when applying it at 30 mg/ kg BW and 100 mg/kg BW (Figure <ref type="figure" target="#fig_3">4C</ref>, right image).</s></p><p><s>Protein analysis of the intracranial tumors revealed reduction of RTK-AXL phosphorylation on Western blot analysis.</s><s>Furthermore, we did not observe compensatory MET kinase activation after 14 days of treatment (Figure <ref type="figure" target="#fig_3">4D</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMS-777607 exerts multiple anti-tumor effects in vivo</head><p><s>The treatment with BMS-777607 revealed multiple anti-tumor effects in vivo.</s><s>In accordance with our in vitro data, BMS-777607 treatment resulted in a reduction of tumor cell proliferation and increase of apoptotic events in SF126 tumor xenografts compared to the control (p = 0.012, Figure <ref type="figure" target="#fig_4">5A</ref> and Figure <ref type="figure" target="#fig_4">5C</ref>, left image).</s><s>Qualitative analysis of Ki67 expression within the tumor tissue showed a decreased proliferative activity under treatment with BMS-777607 (Figure <ref type="figure" target="#fig_4">5B</ref>).</s></p><p><s>Having shown that inhibition of RTK-AXL phosphorylation in endothelial cells also resulted in an impaired tube formation, we also investigated the effect of BMS-777607 treatment on the glioma blood vessel surface and vascular architecture using immunohistochemistry. BMS-777607 reduced glioma vessel surface and vascular size, revealing its anti-angiogenic efficacy (Figure <ref type="figure" target="#fig_4">5B</ref> and Figure <ref type="figure" target="#fig_4">5C</ref>, right image).</s><s>These findings were consistent in the border zone and center of the tumor where different angiogenic activities are usually observed (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Phosphorylated RTK-AXL is abundantly present in both primary and recurrent human GBM specimens</head><p><s>The presented data suggests that therapeutic interference with RTK-AXL phosphorylation using the selective small molecule inhibitor BMS-777607 is an effective means to interfere with multiple aspects of glioma growth.</s><s>Although previous reports have shown that RTK-AXL is expressed in GBM tissue <ref type="bibr" target="#b9">(10)</ref>, it remains unknown whether the RTK-AXL signaling pathway is activated in humans.</s><s>We therefore established a Western Blot analysis, immunoprecipitation, and immunohistochemical staining for P-AXL for human GBM tissue and used normal brain tissue derived from epilepsy surgery as negative control.</s><s>We analyzed 16 GBM samples of patients in the age of 44-77 years (mean age at diagnosis: 63 years).</s><s>8 of them had newly diagnosed GBM, 8 had first recurrence of their GBM following surgery and standard radio-/chemotherapy, and underwent reoperation.</s><s>For the first time, these analyses demonstrated that RTK-AXL is abundantly activated in GBM tissue.</s><s>Western Blot analysis showed strong protein expression as well as phosphorylation of RTK-AXL in both primary and recurrent GBMs with a trend for even higher RTK-AXL expression in recurrent tumors (Figure <ref type="figure" target="#fig_5">6A</ref>, upper and lower image).</s><s>Immunohistochemistry localized P-AXL in tumor cells in hypercellular regions (Figure <ref type="figure" target="#fig_5">6B</ref>, upper left image) as well as in glioma blood vessels of primary GBM (Figure <ref type="figure" target="#fig_5">6B</ref>, lower left image).</s><s>Interestingly RTK-AXL was strongest phosphorylated in tumor cells surrounding necrotic zones, so called pseudo-palisades (Figure <ref type="figure" target="#fig_5">6B</ref>, upper right image).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>The principle findings of our study are that a therapeutic inhibition of RTK-AXL results in a decreased migration and invasion and increase of apoptotic events in glioma cells in vitro and in vivo.</s><s>The targeted inhibition of RTK-AXL phosphorylation leads to a significant decrease in tumor volume or even a complete regression of tumor mass in case of SF126 and U118MG xenografts.</s><s>As previously shown by our group, antitumor effect of RTK-AXL inhibition is related to pro-apoptotic, antiproliferative and anti-invasive effects in the tumor <ref type="bibr" target="#b14">[15]</ref>.</s><s>Our data confirm the role of RTK-AXL as mediator of resistance to apoptosis via caspase 3 signaling <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref>.</s><s>The up-regulation of P-AXL under starving condition explains the idea of an anti-apoptotic feedback loop mechanism.</s><s>Another finding of this study is that we detect an effect of RTK-AXL inhibition toward endothelial cells resulting in an increased ability of tube formation in vitro and less neovascularization in vivo.</s><s>We therefore conclude that inhibition of RTK-AXL leads to an anti-angiogenic effect and therefore represents another possible point of action in glioma therapy.</s></p><p><s>The clinical relevance of RTK-AXL has been illuminated by Hutterer et al. <ref type="bibr" target="#b9">[10]</ref>.</s><s>He presented clinical data showing, that RTK-AXL is mainly expressed in pseudo-palisades and GFAP positive tumor cells, whereas the specific ligand of RTK-AXL Gas6 is expressed in hypoxic border zone but not in pseudopalisades <ref type="bibr" target="#b9">[10]</ref>.</s><s>Our data localizes for the first time areas of phosphorylated RTK-AXL in human GBM tissue.</s><s>RTK-AXL is phosphorylated in different sides of GBM tissue especially in characteristic lesions of this disease like hypercellular zones, pseudo-palisades, and vascular proliferates.</s><s>Activation mechanisms of RTK-AXL were not investigated in this study, but further research has to focus on the role of RTK-AXL-specific ligand Gas6 in GBM.</s><s>Besides activation of RTK-AXL via Gas6 other mechanisms have to be considered like phosphorylation by ROS (reactive oxygen species) and EGFR (epidermal growth factor receptor) interaction <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21]</ref>.</s><s>It has been shown that resistance to EGFR monoclonal antibodies is leading to an up-regulation of AXL <ref type="bibr" target="#b21">[22]</ref>.</s><s>The underlying resistance mechanism is associated with morphological changes from epithelial to mesenchymal phenotype (EMT) in the tumor tissue.</s><s>It has been shown repeatedly that AXL is up-regulated by EMT <ref type="bibr" target="#b22">[23]</ref>.</s><s>For this reason it would be particularly interesting to study a combination therapy with EGFR and RTK-AXL inhibitors to exhibit synergistic effect with respect to tumor control and treatment response.</s></p><p><s>Due to complexity and heterogeneity of GBMs it is unlikely that single molecular therapy would achieve substantial anti-tumoral effect in GBM patients.</s><s>But compared to other targets, inhibition of RTK-AXL leads to multiple anti-cancer effects blocking proliferation, invasion, and angiogenesis.</s><s>This approach displays a clear advantage of the target RTK-AXL in glioma therapy.</s></p><p><s>Despite the promising results with BMS-777607 treatment in a glioma model we have to state, that in very few cases RTK inhibitors made it to clinical use in GBM treatment and most multi-kinase inhibitors did not fulfill expectations in clinical practice <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b23">24]</ref>.</s><s>One point of failure of tyrosine kinase inhibitors in clinical practice is toxicity.</s><s>In case of sunitinib, clinical trials revealed minimal anti-GBM activity and substantial toxicity <ref type="bibr" target="#b24">[25]</ref>.</s></p><p><s>In contrast to this multi-kinase inhibitor, BMS-777607 displays no toxicity defined by weight loss and morbidity at a concentration of 30-50 mg/kg BW in animal models <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s>Detailed information concerning the safety profile and maximum tolerated dose is expected by results of a phase I multiple ascending dose study of BMS-777607 (ClinicalTrials.gov,</s><s>Identifier: NCT01721148) in December 2016.</s><s>Despite toxicity, clinical failure of tyrosine kinase inhibitors in glioma therapy is further associated with kinase switch, mal penetrance of blood brain barrier (BBB) and poor penetrance of tumor tissue.</s><s>Selectivity of BMS-777607 towards Met kinase superfamily (Ron, AXL, Tyro-3, and Mer) has been shown previously <ref type="bibr" target="#b17">[18]</ref>.</s><s>Our results demonstrate that BMS-777607 is inhibiting RTK-AXL at the administered dosage of 12.5 µM in vitro and 30 mg/kg BW in vivo without affecting MET kinase phosphorylation.</s><s>For that reason, we confirm crossing of the BBB and tissue penetrance with the proof of targeted inhibition of RTK-AXL phosphorylation in our xenografts.</s><s>Furthermore we address effects of BMS-777607 as AXL specific in this study.</s><s>So far we did not observe kinase switch toward MET kinase activation.</s><s>Nevertheless even if BMS-777607 might develop anti-MET kinase activity in clinical use, this could lead to a more pronounced antitumor effect knowing of the relevance of Met kinase superfamily in gliomagenesis and glioma progression <ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref>. Yet, research has to focus on resistance mechanisms and suitable drug combinations to overcome escape strategies of these tumors <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b15">16]</ref>.</s><s>Further studies are needed to evaluate RTK-AXL inhibition on patient derived glioma xenografts as basis for application in clinical trials.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Compound</head><p><s>Small molecule tyrosine kinase inhibitor BMS-777607 was purchased by ShangHai Biochempartner Co., Limited (Cas No.:1196681-44-3) with a purity &gt; 98%, which passed an independent quality control check by LC/MS and NMR analysis at the Lead Discovery Center GmbH, Dortmund Germany.</s><s>BMS-777607 (MW: 512.90 g/mol) was recently published as a MET kinase inhibitor (IC 50 = 3.9 nM), but has been shown to be more selective for AXL (IC 50 = 1.1 nM) <ref type="bibr" target="#b17">[18]</ref>.</s><s>IC 50 value of BMS-777607 was determined in MTT assay for each cell assessing at least 8 different concentrations.</s><s>According to the results, the in vitro assay concentration of BMS-777607 was 12.5 µM.</s><s>The compound was diluted in DMSO (Roth) and DMEM (Gibco).</s><s>The control group was treated with equal amounts of solvent.</s></p><p><s>In vivo compound was used at a concentration of 30-100 mg/kg of body weight (BW).</s><s>The compound was diluted in DMSO and PEG300 (Sigma Aldrich).</s><s>The compound was administered twice a day via intraperitoneal (i.p.) injection.</s><s>The control group received injections containing the solvent agents.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell culture</head><p><s>Human high-grade glioma cells U118MG were obtained from American Type Culture Collection (ATCC).</s><s>Human high-grade glioma cells SF126 were obtained from the JCRB Cell Bank.</s><s>Both were primary tumor cell cultures derived from surgical specimens of human GBM, WHO Grade IV.</s><s>Cell authentication was carried out with LGC Standards Cell line Authentication service in June 2014 with 16 loci service of short tandem repeat profile.</s><s>Tumor cells were maintained as monolayer cultured in tumor growth medium at 37°C, 5% CO 2 , 95% humidity in a tissue culture incubator.</s><s>Growth medium was comprised of Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal calf serum (FCS) and 1% antibiotics (penicillin/steptamycin).</s><s>Prior starting experiments, each cell population was grown in equal (80%) confluence in culture dishes under normal conditions or starving conditions (culture medium containing 0% FCS).</s><s>Cell count and cell vitality was assessed with CASY ® Cell Counter TT (OLS).</s></p><p><s>HUVEC cell line was obtained from PromoCell.</s><s>Cells were cultured accordingly to manufactures instructions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Spheroids</head><p><s>Cells were relabeled prior forming spheroids with DiI (invitrogen) according to manufactures instructions.</s><s>Cells were seeded in an uncoated, non-adhesive 96-well plate (Sarstedt).</s><s>Culture medium contained 20% Methocell medium consisting of 6 gr.</s><s>carboxymethylcellulose (Sigma Aldrich) and 250 ml of the preheated ECBM (Endothial cell growth medium, Lonza).</s><s>5.000 cells were plated per well in 100 µl Methocell medium.</s><s>Spheroids grew within 48 hours.</s><s>Round-shaped spheroids were selected for experiments with a diameter size of 300-500 µm.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell viability assay-MTT assay</head><p><s>5.000 cells were seeded per well of a 96-well plate in triplicates and incubated with 0.1 ml DMEM supplemented with 5% FCS.</s><s>Fractions were treated with DMSO or treated with compound at different concentrations (1.56 µM-50 µM).</s><s>Culture medium was replaced or exchanged after 24, 48 and 72 hours.</s><s>100 µl of MTT reagent (Thiazolyl Blue Tetrazolium Bromide, Sigma) was added and incubated for 3 hour.</s><s>Crystals were solved with 100 µl DMSO-isopropanol (Sigma Aldrich) (1:1) under constant shacking for 10 minutes.</s><s>Absorption of supernatant was measured at 570 nm with plate reader (infinite200).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Apoptosis assay</head><p><s>Apoptosis was measured with caspase3/CPP32 Colorimetric Assay Kit (Biovision).</s><s>Cells were cultured for 24 hours with 50 ng/ml TNF-alpha (Dianova) or with compound at a concentration of 12.5 µM.</s><s>The noninduced control was treated with solvent DMSO at a final concentration of 0.5% (Sigma Aldrich).</s><s>200 µg protein were incubated with 2 × Reaction buffer containing 10 mM DTT and DEVD-pNA substrate.</s><s>Absorption was determined at 405 nm.</s><s>Fold increase in CPP32 activity was determined by comparing results of treated group with the level of the non-induced control.</s><s>Assay was performed in triplicates for the calculation of mean values and standard deviation (n = 3).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Boyden chamber migration assay</head><p><s>Experiments were performed with 50.000 cells per chamber.</s><s>Prior starting the experiment the inserts were coated with fibronectin (Sigma Aldrich) at a final concentration of 10 µg/ml in cold PBS.</s><s>Inserts were incubated with fibronectin for 2 hours in the cell incubator.</s><s>Cell suspension and compound were added to the upper chamber (compound concentration: 12.5 µM).</s><s>The lower chamber was filled with 110 µl of fibroblast-conditioned medium (FCM) to stimulate cell migration.</s><s>A filter with 8 µm pore size separated the upper and lower chamber.</s><s>After a migration time of 3 hours, cells adhering to the bottom side of the filters were fixed with methanol for 5 minutes.</s><s>The inserts were dried for 5 minutes and then stained with DAPI (Sigma Aldrich, diluted in PBS 1:100).</s><s>Cells per field were counted at a magnification of 10 fold, 4 fields per filter were averaged (n = 5).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Orthotopic brain slice invasion assay</head><p><s>For preparation of brain slice cultures, 3 to 6-daysold mouse pups (C57BL/6NCrl, Charles River) were used.</s><s>Brain hemispheres were sectioned in 300 µm thick coronary slices (McIllwain tissue chopper).</s><s>Slices were separated in ice cold dissection medium containing 99 ml MEM and 1 ml glutamine (Gibco) and cultured onto semipermeable membrane of inserts (Transparent PET membrane, 1.6 × 10 6 -pores/cm², BD, Falcon ® ) with 1 ml culture medium containing 23 ml MEM (Gibco21575), 12.5 ml Horse serum, 12.5 ml BME (Gibco 41010), 1.5 ml of 20% glucose (Roth) and 0.5 ml Glutamine (Life Technologies, L-Glutamine 200 mM).</s><s>Medium was replaced every two days.</s><s>24 hours after cultivation prelabeled spheroids were placed in the area between striatum and corpus callosum.</s><s>Invasion of DiI-labeled cells were monitored using confocal microscopy.</s><s>After 8 days slices were fixed in 4% PFA for 2 hours at 37°C.</s><s>Nuclear staining of slices was performed with To-PRO-3 according to manufacturer's instructions (Life Technologies).</s><s>Slices were transferred onto glass slides (Langenbrinck) and mounted in mounting medium (Immuno mount, Thermo Scientific) for confocal analysis.</s><s>Confocal analysis was performed with Zeiss Confocal microscope.</s><s>For quantitative analysis distance of invaded cells from border of spheroid was measured (n = 8).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tube formation assay</head><p><s>10 µl BD matrigel basement membrane matrix (BD 354230) was pipetted to a 15-well plate (µ-Slide Angiogenesis, ibiTreat), matigel solution formed gel within 30 minutes incubation time at 37°C.</s><s>Harvested HUVEC cells were suspended in a concentration of 200 000 cells/ml with 12.5 µM concentration of compound or vehicle (0.5% DMSO).</s><s>50 µl of cell suspension pro well was added onto solidified gel and incubated for 4 to 20 hours.</s><s>Tube formation was analyzed with Zeiss Axiovision fluorescence microscope.</s><s>Tube length and branching points were quantified using online service Wimasis Image Analysis (n = 5).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Experimental tumor models</head><p><s>Athymic CD-1 Nu/Nu nude mice (female, obtained from Charles River) were maintained within a pathogen germ-free environment and were used at 6-10 weeks of age.</s><s>The weight ranges was in a range of 20 to 28 gram.</s><s>Experiments were performed in accordance with the approved institutional protocol and the guidelines of the Institutional Animal Care and Use Committee.</s><s>General anesthesia was induced with 7% Ketaminhydrochlorid (Ketavet, Pfizer), 8% Xylaxine (Rompun 2%, Bayer) dissolved in aqua via i.p. injection.</s><s>Phenoxymethylpenicillin (InfectoCilin, 5 Mega) was administered via intramuscular injection.</s><s>For stereotactic tumor cell implantation, mice were positioned in the stereotactic platform.</s><s>A longitudinal skin incision was performed in the mid scalp extending from the ears caudally.</s><s>The burr hole was drilled with a syringe of 23′G 2 mm posterior and 1.5 mm laterally to bregma.</s><s>Hamilton syringe was loaded with glioma cells dissolved in DMEM without FCS.</s><s>Hamilton syringe was inserted gently to a depth of 4 mm.</s><s>After injection wound was closed with suture (Prolene 2.0, Ethicon).</s><s>Finally, mice were placed on a heating plate set to 37°C until regaining consciousness.</s><s>Drinking water was enriched with tramadol calculating 15 mg/kg BW (Grünenthal).</s><s>Contrast enhanced MRI (gadopentetate dimeglumine; Magnesvist, Bayer) scans were performed under anesthesia with 7T Bruker MRI (PharmaScan 70/16 US, Bruker Software Paravision 5.1).</s><s>Tumor volumetric analysis was carried out with Analyze 10.0 and ImageJ software.</s><s>Mice were sacrificed at day 14 and the body was perfused with PBS under anesthesia.</s><s>The whole brain or tumor was dissected and immediately frozen in liquid nitrogen and stored at −80°C (n = 7).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunoprecipitation (IP)</head><p><s>IP was performed using Protein A-Sepherose 4A beads (Life Technologies).</s><s>Low salt IP-lysis buffer was enriched with Halt ™ Phosphatase Inhibitor Single-Use Cocktail (Thermo Scientific) and Halt Protease Inhibitor Single-Use Cocktail (Thermo Scientific).</s><s>Immuncomplexes were prepared with 200 µg protein and 1:50 dilution of anti-AXL (C89E7) rabbit antibody (Cell Signaling).</s><s>Assay was performed according to previous protocol <ref type="bibr" target="#b13">(14)</ref>.</s><s>Detection of RTK-AXL phosphorylation was determined using antibody 4G10 mouse antityrosine antibody (Max Planck Institute of Biochemistry, Dilution 1:2.000).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Western blotting (WB)</head><p><s>Protein samples were boiled for 5 min with Laemmli sample buffer (Bio-Rad Laboratories) and loaded into pre-poured Tris-HCl-glycine SDS-PAGE gels (stacking gel 4%, resolving gel 6% or 8%).</s><s>Gels run at 150 V for 1.5 hours following transfer to a polyvinylidene difluoride membrane (PVDF, Bio-Rad Laboratories) at 40 mA constant current for 2 h.</s><s>Blots were blocked with 5% BSA in 1xTBST, primary and secondary antibodies were dissolved in TBST.</s><s>Following primary antibodies were used.</s><s>R &amp; D Systems: human phopho-AXL (Y779) mAb (Clone 713610), Cell Signaling: anti-AXL C89E7 rabbit mAb, phospho-MET (Tyr1234/1235) rabbit mAb (D26) XP ® .</s><s>Santa Cruz: Gas6 antibody (C-20).</s><s>Sigma Aldrich: mouse monoclonal β-actin antibody (clone 1A4).</s><s>Immunocomplexes were visualized using a second HRP-conjugated anti-rabbit or anti-mouse antibody (Pierce Biotechnology).</s><s>For development we used ECL Kit (Sigma).</s><s>ImageJ Software was used for densitometry analysis.</s><s>Reported values were first normalized to the loading control and then multiplied by a constant to reach the lowest whole integral.</s><s>Each western blot was carried out with a negative control consistent of sample diluent or beads incubated with antibody and sample diluent only.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunohistochemistry and immunofluorescence cells</head><p><s>Adherent cells were plated onto cover slips and fixed with 4% PFA for 10 minutes at room temperature.</s><s>Cells were blocked with 1% casein for 45 minutes at room temperature.</s><s>Antibodies were diluted in 0.5% casein.</s><s>The primary antibody was incubated for one to two hours, the secondary antibody for one hour.</s><s>Wash steps were carried out with TBST.</s><s>Negative control was carried out without primary antibody incubation and is shown in Supplementary Figure <ref type="figure" target="#fig_0">S1</ref> for anti-AXL antibody and antiphospho-AXL antibody.</s></p><p><s>For immunofluorescence human phopho-AXL (Y779) mAb (Clone 713610, R &amp; D Systems) and anti-AXL C89E7 rabbit mAb (Cell Signaling) were used.</s><s>The following secondary, fluorescently labeled antibodies were used: FITC-conjugated donkey anti-rabbit IgG (Dianova, 711-095-152), Cy3-conjugated donkey anti-mouse IgG (Dianova, 115-165-146).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mouse tissue</head><p><s>Mouse brain was mounted in paraffin block in a.p. orientation.</s><s>8-20 µm coronary sections were prepared with cryostat (Microm Cryo-Star HM 560 Cryostat, GMI).</s></p><p><s>Sections were fixed with PFA 4%.</s><s>Staining of intratumoral vessels and proliferation was carried out with purified rat anti-mouse CD31 antibody (clone MEC13.3,</s><s>BD Pharmingen ™ ) and rabbit anti-Ki-67 antigen monoclonal antibody (clone SP6, Diganostic BioSystems).</s><s>The following secondary, fluorescently labeled antibodies were used: FITC-conjugated donkey anti-rabbit IgG (Dianova, 711-095-152), Cy3-conjugated donkey anti-rat IgG (Dianova, 712-165-153).</s><s>Apoptotic activity within the tumor was assessed using Apoptaq kit (Millipore).</s><s>Staining procedure was done according to manufacturer´s instructions.</s></p><p><s>Tissue staining for AXL and phospho-AXL was carried out on PFA fixed slices.</s><s>Cells and brain slices were finally counterstained with DAPI (Thermo Scientific).</s><s>Slices were analyzed using a fluorescence microscope (Zeiss).</s></p><p><s>For statistical analysis we used ImageJ software.</s><s>For qualitative analysis of fluorescent signal, all parameters were maintained as set for the initial image.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human tissue</head><p><s>Immunohistochemical staining of formalin-fixed, paraffin-embedded (FFPE) tissue sections (4 μm-thick) was performed on a VENTANA Benchmark XT automated staining instrument according to the manufacturer's instructions.</s><s>Slides were de-paraffinized using EZ prep solution (Ventana Medical Systems, Tucson, AZ) for 30 minutes at 75°C.</s><s>Antigen retrieval was accomplished on the automated stainer using CC1 solution (Ventana Medical Systems, Tucson, AZ) for 60 minutes at 95°C.</s><s>Briefly, the anti-phospho-AXL antibody (Human Phospho-AXL (Y779) monoclonal mouse IgG Clone 713610, R &amp; D Systems, dilution 1:50) was applied and developed using the iVIEW DAB Detection Kit (Ventana Medical Systems).</s><s>All slides were then counterstained with hematoxylin for 4 minutes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient data</head><p><s>Clinical data was assessed under an institutional review board-approved protocol and de-identified for patient confidentiality.</s><s>We included 16 GBM patients, which have been treated in our institution in the year 2015.</s><s>GBM diagnosis was assured of two independent neuropathologists.</s><s>RTK-AXL and phospho-AXL expression was quantified with IP and WB analysis in 8 patients with primary GBM and in 8 patients with recurrent disease, which received re-resection.</s><s>FFPE tissue sections of these individual 16 patients were stained with anti-phospho-AXL antibody.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Microscopy</head><p><s>Images were recorded by fluorescent microscope from Zeiss (Obeserver Z1).</s><s>Following objectives were used: 5× EC PlnN, 5×/0.16</s><s>DIC0 (resolution: 2.0 µm), 10× Pln Apo, 10x/0.45</s><s>DIC II (resolution: 0.74 µm), 20× Pln Apo, 20×/0.8</s><s>DIC II (resolution: 0.42 µm).</s><s>We use a HAL 100 and detectors for DAPI, GFP and DSRed.</s><s>Pictures were processed and recorded with Image software Axio Vision Rel.</s><s>4.8.</s><s>Statistical analysis was carried out with ImageJ Software 1.46r.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Each group consisted of at least triplicates.</s><s>In vivo experiments were performed with five or more animals per group.</s><s>Animals were de-identified for blinded analysis of MRI volumetry and IHC analysis.</s><s>Statistical analysis was performed using GraphPad Prism, Version 5.0c.</s><s>For statistical test we used Student´s T-Test and one-way ANOVA combined with Bonferroni´s multiple comparison test.</s><s>Significance level was set at alpha = 0.05 (95% confidence intervals).</s><s>The level of significance was set at *p &lt; 0.05.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc><div><p><s>Figure 1: (A) RTK-AXL expression of U118MG and SF126 cells in vitro.</s><s>(B) RTK-AXL expression of U118MG and SF126 xenografts in vivo.</s><s>Scale bar indicates 50 µm.</s><s>(C) left image: Western blot showing base line expression of RTK-AXL in cell lysates of U118MG and SF126 (− = negative control).</s><s>(C) right image: Western blot analysis of changes in the phosphorylation of RTK-AXL under starving conditions compared to standard culture conditions (− = negative control).</s><s>(D) IC 50 of U118MG and SF126 cells after treatment with BMS-777607 for 4 and 12 hours.</s></p></div></figDesc><graphic coords="3,127.33,161.00,358.34,502.15" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 :</head><label>2</label><figDesc><div><p><s>Figure 2: (A) left image: Western blot with IP of phosphorylated RTK-AXL and MET-kinase with cell lysates after 12 hours treatment with 12.5 µM BMS-777607 (− = negative control).</s><s>(A) right image: Statistical analysis of P-AXL expression of three independent replicates (n = 3, ***p &lt; 0.0001).</s><s>(B) and (C) IHC of P-AXL in U118MG and SF126 after treatment with vehicle and BMS-777607.</s><s>(D) left image: MTT results after repeated treatment with 12.5 µM BMS-777607 every 12 hours (n = 5, **p = 0.0011, *p = 0.025).</s><s>(D) middle image: Results of apoptosis assay 24 hours after single treatment with 12.5 µM BMS-777607 (n = 3, **p = 0.0045, *p = 0.0289).</s><s>(D) right image: Boyden chamber migration assay after 3 hours migration time under treatment with 12.5 µM BMS-777607 (n = 5, **p = 0.0045, *p = 0.0228).</s></p></div></figDesc><graphic coords="4,135.49,170.75,341.02,480.01" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 :</head><label>3</label><figDesc><div><p><s>Figure 3: (A) Orthotopic brain slice invasion assay with implanted, DiI stained tumor cell spheroids of cell line U118MG.</s><s>Images show data at day 8 under daily administration of BMS-777607 with corresponding statistical analysis (n = 8, **p = 0.0040).</s><s>Results were obtained with confocal microscopy.</s><s>Scale bar indicates 10 µm.</s><s>(B) Expression of AXl and P-AXL in HUVECs (− = negative control).</s><s>(C) IC 50 value of BMS-777607 treatment in HUVECs.</s><s>(D) left images: Tube formation assay with HUVECs after 4 and 20 hours and single administration of 12.5 µM BMS-777607.</s><s>(D) right images: Statistical analysis at 4 and 20 hours of tube length (n = 5, 4 h: ***p &lt; 0.0001, 20 h: ***p &lt; 0.0001) and branching points (n = 5, 4 h: *p = 0.035, 20 h: ***p &lt; 0.0001).</s></p></div></figDesc><graphic coords="5,119.76,157.00,374.47,492.58" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 :</head><label>4</label><figDesc><div><p><s>Figure 4: (A) MRI results of U118MG after 7 days of treatment with 30 mg/kg BW BMS-777607 (BMS30, n = 7) and vehicle at day 14 (n = 7).</s><s>(B) MRI results of SF126 after 11 days of treatment with 30 mg/kg BW (BMS30, n = 5), 100 mg/kg BW BMS-777607 (BMS100, n = 7), and vehicle (n = 7) at day 14.</s><s>MRI images are contrast enhanced.</s><s>(C) Both images display tumor volumetric analysis after 14 days experiment.</s><s>U118MG vehicle vs. BMS30 **p = 0.0012.</s><s>SF126 vehicle vs. BMS30: *p = 0.015, vehicle vs. BMS100: **p = 0.0013, BMS30 vs. BMS100: ns.</s><s>(D) left image: Western blot analysis with regulation of RTK-AXL and MET kinase phosphorylation on intracranial tumor tissue after i.p. administration of BMS-777607 at day 14 (− = negative control).</s><s>(D) right image: Statistical analysis of three independent experiments of Western blot with tumor lysates (n = 3, ***p &lt; 0.0001).</s></p></div></figDesc><graphic coords="6,99.76,49.00,415.49,589.82" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5 :</head><label>5</label><figDesc><div><p><s>Figure 5: (A) Intratumoral apoptotic events in SF126 xenografts under treatment with BMS-777607 and vehicle.</s><s>(B) CD31 staining (red) shows differences in vessel size and density under treatment with BMS-777607 in vivo.</s><s>Proliferative activity is displayed qualitatively with Ki67 staining (green).</s><s>(C) Images show corresponding statistical analysis of apoptotic events within tumor tissue (n = 3, *p = 0.0121) and statistical analysis of intratumoral vessel density (n = 3, ***p &lt; 0.0001).</s><s>Scale bar indicates 50 µm.</s></p></div></figDesc><graphic coords="8,104.72,164.44,404.57,505.66" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 6 :</head><label>6</label><figDesc><div><p><s>Figure 6: (A) Upper left blot shows IP of phosphorylated RTK-AXL in 8 patients with primary glioblastoma multiforme (pGBM), lower blot shows phosphorylated RTK-AXL in 8 patients with recurrent glioblastoma multiforme (rGBM).</s><s>Upper right blot shows following control samples: positive ctrl: SF126 tumor mice, patient #37: meningeoma WHO°I, patient #20: arachnoidal cyst, negative ctrl: beads incubated with antibody and sample diluent.</s><s>(B) Staining of phosphorylated RTK-AXL in human glioblastoma multiforme tissue (huGBM).</s><s>Upper left image shows membrane bound staining of tumor cells (arrow).</s><s>Scale bar of upper left image indicates 10 µm.</s><s>Lower left image shows staining of phosphorylated RTK-AXL of tumor vessels (arrow).</s><s>RTK-AXL phosphorylation is also observed in tumor pseudopalisades (arrow) adjacent to necrotic areas (star, upper right image).</s><s>Lower right images shows negative control staining of healthy brain tissue.</s><s>Scale bar indicates 50 µm.</s></p></div></figDesc><graphic coords="9,110.95,49.54,392.09,577.90" type="bitmap" /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">www.impactjournals.com/oncotarget</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>The authors thank Petra Matylewski for establishing the staining of human tissue and excellent technical assistance.</s><s>We further thank Susanne Müller for technical support with animal MRI.</s></p><p><s>We thank ShangHai Biochempartner Co. for purchasing BMS777607.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GRANT SUPPORT</head><p><s>This work was supported by a grant from Berliner Krebshilfe, Germany (Z: ONFF201502).</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICTS OF INTEREST</head><p><s>No conflicts of interest exists in the submission of the manuscript and the manuscript is approved by all authors for publication.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Brain tumors</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Deangelis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">344</biblScope>
			<biblScope unit="page" from="114" to="123" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide</title>
		<author>
			<persName><forename type="first">R</forename><surname>Stupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Dietrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ostermann</forename><surname>Kraljevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Maeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Meuli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Janzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pizzolato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Miralbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Porchet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Regli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>De Tribolet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1375" to="1382" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</title>
		<author>
			<persName><forename type="first">R</forename><surname>Stupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Mason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Van Den Bent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Taphoorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Belanger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Brandes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Marosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Bogdahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Curschmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Janzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Ludwin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">352</biblScope>
			<biblScope unit="page" from="987" to="996" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Epidemiology and molecular pathology of glioma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Schwartzbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Aldape</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wrensch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Clin Pract Neurol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">516</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Hongo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kallop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ludlam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pei</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="3442" to="3455" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Axl-dependent signalling: a clinical update</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Korshunov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Sci (Lond)</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="361" to="368" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Linger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Cummings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sather</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Migdall-Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Middleton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Baron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Franklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Merrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jedlicka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Deryckere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Heasley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="3420" to="3431" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ohashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nakano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hanafusa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mizuno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">271</biblScope>
			<biblScope unit="page" from="30022" to="30027" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">AXL is a potential target for therapeutic intervention in breast cancer progression</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Knyazev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">V</forename><surname>Cheburkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Knyazev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Orfi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Szabadkai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Daub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Keri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ullrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1905" to="1915" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Axl and growth arrestspecific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hutterer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Knyazev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reschke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Maier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Stefanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Knyazeva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Barbieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reindl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muigg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kostron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stockhammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ullrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="130" to="138" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Lay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Chuang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">268</biblScope>
			<biblScope unit="page" from="314" to="324" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">IUBMB Life</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="507" to="518" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Linger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Keating</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Earp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Graham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Ther Targets</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1073" to="1090" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Paolino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Choidas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wallner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pranjic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Uribesalgo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loeser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Jamieson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Langdon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Fededa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Cronin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nitsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schultz-Fademrecht</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">507</biblScope>
			<biblScope unit="page" from="508" to="512" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Dominant-negative www.impactjournals.com/oncotarget inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival</title>
		<author>
			<persName><forename type="first">P</forename><surname>Vajkoczy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Knyazev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kunkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Capelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Behrndt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Von Tengg-Kobligk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kiessling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Eichelsbacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Essig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Read</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Erber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ullrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="5799" to="5804" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Keating</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Donson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ware</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mulcahy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Salzberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Foreman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thorburn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Graham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1298" to="1307" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Rho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Bae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="253" to="262" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl )-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>An</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">W</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">T</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Cornelius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gullo-Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Henley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jeyaseelan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kamath</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Chem</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1251" to="1254" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Brain tumor invasion model system using organotypic brain-slice culture as an alternative to in vivo model</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Rhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">I</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yang</forename><surname>Sy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Bae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Ahn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cancer Res Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="469" to="476" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Olivas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Au</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Laframboise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abdel-Rahman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Rho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="852" to="860" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Seeing the big picture</title>
		<author>
			<persName><forename type="first">Rogers</forename><forename type="middle">S</forename><surname>Seton</surname></persName>
		</author>
		<author>
			<persName><surname>Signalling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">683</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Kalinowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Candy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Epis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Stuart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Goodall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Leedman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="2541" to="2558" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">AXL induces epithelial-tomesenchymal transition and regulates the function of breast cancer stem cells</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Asiedu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Beauchamp-Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Ingle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Radisky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Knutson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1316" to="1324" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Vouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>An</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Birt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Pilkington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hafizi</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.3952</idno>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="16183" to="16197" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hutterer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nowosielski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Haybaeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Embacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Stockhammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gotwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Holzner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Capper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Preusser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Marosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Oberndorfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Moik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Buchroithner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuro Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="92" to="102" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors</title>
		<author>
			<persName><forename type="first">S</forename><surname>Patyna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Arrigoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Terron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Heward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Vonderfecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Denlinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Turnquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Evering</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Toxicol Pathol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="905" to="916" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guessous</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dipierro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mudrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Johnson</forename><forename type="middle">E</forename><surname>Marcinkiewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Engelhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kefas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schiff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Abounader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="376" to="385" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">High levels of c-Met is associated with poor prognosis in glioblastoma</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Petterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Dahlrot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Hermansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Gundesen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wohlleben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rasmussen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Beier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Kristensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurooncol</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="517" to="527" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title level="m" type="main">Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer</title>
		<author>
			<persName><forename type="first">Rma</forename><surname>Linger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Keating</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Earp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><surname>Tam Receptor Tyrosine Kinases</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="35" to="83" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Targeting Axl and Mer kinases in cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Verma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Warner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vankayalapati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Bearss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sharma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1763" to="1773" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Diversification of TAM receptor tyrosine kinase function</title>
		<author>
			<persName><forename type="first">A</forename><surname>Zagorska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Traves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Lew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Dransfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lemke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="920" to="928" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
